A combination of the BCL-2 inhibitors ABT-263 and A-1210477 inhibited cell proliferation 35 in the HeLa, C33A, SiHa and CaSki human cervical cancer cell lines. Drug sensitivity was 36 initially tested using 2-dimensional (2D) cell culture models. As ABT-263 binds to both BCL-37 2 and BCL-XL at high affinity, it was unclear whether the synergism of the drug combination 38 was driven either by singly inhibiting BCL-2 or BCL-XL, or inhibition of both. Therefore, we 39 used the BCL-2 selective inhibitor ABT-199 and the BCL-XL selective inhibitor A1331852 to 40 resolved the individual antitumor activities of ABT-263 into BCL-2 and BCL-XL dependent 41 mechanisms. A-1210477 was substituted with the orally bioavailable S63845. The SiHa, C33A 42 and CaSki cell lines were resistant to single agent treatment of all three drugs, suggesting that 43 none of these anti-apoptotic proteins singly mediate survival of the cells. HeLa cells were 44 resistant to single agent treatment of ABT-199 and A1331852 but were sensitive to S63845 45 indicating that they depend on MCL-1 for survival. Co-inhibition of BCL-XL and MCL-1 with 46 A1331852 and S63845 significantly inhibited cell proliferation of all four cell lines. Similar 47 data were obtained with 3-dimensional spheroid cell culture models generated from two 48 cervical cancer cell lines in vitro. Treatment with a combination of A1331852 and S63845 49 resulted in inhibition of growth and invasion of the 3D spheroids. Co-inhibition of BCL-2 and 50 MCL-1 with ABT-199 and S63845, also inhibited cell proliferation of all cancer cell lines, 51 except SiHa. However, the effect of the combination was not as pronounced as combination of 52 A1331852 and S63845. Collectively, our data demonstrate that the combination of MCL-1-53 selective inhibitors with either selective inhibitors of either BCL-XL or BCL-2 may be 54 potentially useful as treatment strategies for the management of cervical cancer. 55 56
Introduction 60
The BCL-2 family proteins are crucial regulators of the intrinsic apoptosis pathway. 61
These proteins can be divided into pro-apoptotic and anti-apoptotic proteins and have one to 62 four BCL-2 homology motifs (BH1-BH4). The anti-apoptotic multidomain (BH1-BH4) 63 members namely BCL-2, BCL-XL, BCL-w, BFL-1/A1 and MCL-1 function to counteract the 64 pore-forming activity of the pro-apoptotic multidomain proteins (BH1-BH4), BAX and BAK 65 which permeabilize the mitochondria outer membrane. Following various stress signals, the 66 BH3-only proteins either neutralize the anti-apoptotic proteins or directly activate effector 67 proteins BAX and BAK which will eventually lead to apoptosis in cells [1, 2] . 68
One strategy that cancer cells employ to evade apoptosis, triggered by oncogenesis or 69 drug treatment is via overexpressing the BCL-2 anti-apoptotic proteins [3] . Hence, treatment 70 that is effective in activating pro-death signaling either by upregulating pro-apoptotic protein 71 BIM or effector proteins BAX or BAX are inefficient as cancer cells can survive the cytotoxic 72 insult by sequestering pro-apoptotic proteins with anti-apoptotic proteins [4] . Cellular anti-73 apoptotic mechanisms can also be suppressed by BCL-2 selective inhibitors [4] , which mimic 74 the action of certain BH3-only proteins. For example, ABT-263 (Navitoclax) mimics the BH3-75 only protein BAD which selectively inhibits BCL-2, BCL-XL and BCL-w [5] . ABT-263 has 76 also demonstrated anti-tumor activity in lymphoid malignancies in clinical studies, but induced 77 dose-dependent thrombocytopenia as a consequence of inhibiting BCL-XL [6, 7] . This toxicity 78 prompted the development of the BCL-2 selective inhibitor ABT-199/venetoclax [8] . 79 Venetoclax was approved by FDA for the treatment of chronic lymphocytic leukemia (CLL) 80
[9] but has shown activity in other cancers such as acute myeloid leukemia (AML) [10] and T-81 cell acute lymphoblastic leukemia (T-ALL) in combination with the MCL-1 selective inhibitor 82 S63845 [11] . In order to determine the contribution of BCL-XL for survival of cancer cells, a 83 number of specific BCL-XL inhibitors such as WEHI-539 [12], A1331852 and A1155463 [13] 84 have been developed. 85
In this present study, ABT-199 and A1331852 [13] were used experimentally to 86 investigate the contributions of BCL-2 and BCL-XL in mediating cervical cancer cell survival. 87
In order to study the role of MCL-1 for cell survival, S63845, a small molecule inhibitor of 88 MCL-1 was employed. S63845 was reported to demonstrate higher affinity towards MCL-1 89 (Ki < 1.2nM) compared to A-1210477 (Ki = 28 nM). In addition, S63845 was 1000-fold more 90 potent in killing (MCL-1 dependent) H929 cells compared to A-1210477 [14] , and its use 91 therefore would be more appropriate in helping delineate its role in cervical cancer cell 92
survival. 93
Four cervical cancer cell lines C33A, SiHa, HeLa and CaSki were subjected to single 94 agent treatment of ABT-199, A1331852 and S3845. The cells were also tested with 95 combinations of A1331852/S63845 and ABT-199/S63845 in monolayer (2D) culture and in 3-96 dimensional (3D) spheroids, which provide a microenvironment closer to tumours in vivo [15] . 97 98 2. Material and Methods 99
Drugs and Cell Lines 100
ABT-199, A1331852 and S63845 (MedChemExpress, NJ, USA) were dissolved in dimethyl 101 sulfoxide (DMSO) at a stock concentration of 10 mM. All four cell lines were purchased from 102 the American Type Culture Collection (Manassas, VA, USA), and maintained in culture as 103 described previously [16] . 104 105
Drug sensitivity assay 106
Drug sensitivity assays were performed as described previously [17] . Cells were first subjected 107 to ABT-199, A1331852 and S63845 treatment alone or in combination for 72 hours. Sensitivity 108 of cells to drug combinations was measured by testing a fixed concentration of S63845 with 109 increasing concentrations of either A1331852 or ABT-199. Cell proliferation was quantified 110 by fluorescence using SYBR Green as described previously [16] . All drug sensitivity assays 111 were conducted four times (n = 4) and average IC50 values were calculated from the 112 experimental data. 113 114
Three-dimensional spheroids 115
Approximately 5000 cells (2.5 x 10 4 cells/ml) cells were seeded in an Ultra-Low Attachment 116 (ULA) 96-well U bottom-plate (Corning, NY, USA). Plates containing the cells were 117 centrifuged at 1200 rpm for 2 minutes. Plates were incubated at 37 0 C, 95% O2, 5% CO2 for 72 118 hours. After 72 hours, 3D spheroids were embedded into collagen mix [18] . Spheroids were 119 treated with A1331852, ABT-199 and S63845, alone and in combination for 72 hours. 120
Spheroid growth and invasion were photographed every 24 hours using a Nikon C2+ inverted 121 confocal microscope. Upon termination of the assay, live-dead staining of spheroids was 122 conducted as described in [19] . Images were taken using a Nikon-300 inverted fluorescence 123 microscope. 124 125 3. Results 126
Selective BCL-2 inhibitors resolve the individual contributions of anti-apoptotic proteins 127
BCL-2, BCL-XL and MCL-1 for cervical cancer cell lines survival 128 129
HeLa cells were resistant to single agent treatment with A1331852 ( Fig. 1a & Table S1 ) and 130 ABT-199 ( Fig. 1b & Table S1 ) but sensitive to single agent treatment with S63845 ( Fig. 1c & 131 Table S1 ). C33A ( Fig. 1a -c & Table S1), and SiHa ( Fig. 1a -c & Table S1 ) cells were resistant 132 to single agent treatment with all three BCL-2 selective inhibitors. CaSki cells were slightly 133 sensitive to A1331852 ( Fig. 1a & Table S1 ), but were resistant to single agent ABT-199 ( Fig.  134 appears that co-inhibition of other anti-apoptotic proteins are necessary for more effective 136 killing of the CaSki cells. 137
Collectively, these data suggest that insensitivity of HeLa cells to single agent treatment 138 of ABT-199 and A1331852 shows that they depend on MCL-1 for survival, as the cells were 139 susceptible to single agent treatment of S63845. Insensitivity of the other cell lines to all three 140 BCL-2 selective drugs used as monotherapy suggest that the cells are resistant to apoptosis due 141 to the need to target multiple pro-survival proteins rather than just one. These data also suggest 142 that other death mechanisms and pathways may be responsible for apoptotic death mechanisms 143 in these cells. For example, it has been demonstrated that there are non-caspase dependent cell 144 death mechanisms that are dependent on the cathepsins [20]. 145 146
Substantial inhibition of cell proliferation driven by co-inhibition of BCL-XL and 147
MCL-1 148 149
As HeLa cells were sensitive to single agent S63845 ( Fig. 1c & Table S1 ), we tested the 150 sensitivity of HeLa to fixed doses of S6835 (doses below 1 µM) with increasing concentrations 151 of either A1331852 or HeLa cells were treated with either a fixed dose of 0.25 µM or 0.5 µM S63845 and 153 increasing concentrations of A1331852 (0 -32 µM). At a concentration of 0.25 µM S63845, 154 the dose-response curve substantially moved to the left ( Fig. 2a ). 0.25 µM S63845 sensitized 155 HeLa cells to A1331852 by 44-fold (Table S2 ). Similar data were obtained when the 156 concentration of S63845 was increased to 0.5 µM ( Fig. 2a & Table S2 ). In C33A cells, the 157 presence of 0.5 µM S63845, shifted the dose-dependent curve substantially to the left ( Table S2 ) and sensitized the cells to A1331852 close to 100-fold (Table S2 ). Addition of 1 159 µM and 2 µM S63845 ( Fig. 2b & Table S2 ) resulted in similar data. Comparably, in the 160 presence of 0.5 µM S63845 (Fig. 2c ), SiHa cells were sensitized to A1331852 by 100-fold 161 (Table S2 ). Similar data were obtained in SiHa cells when the concentration of S63845 was 162 increased to 1 µM and 2 µM ( Fig. 2c & Table S2 ). In CaSki cells, combination with S63845 163 sensitised the cells to A1331852 for all concentrations tested ( Fig. 2d & Table S2 ) indicating 164 that co-inhibition with MCL-1, enhances cell killing compared to inhibition of BCL-XL alone. 165
The CI values obtained for combination of A1331852 and S63845 exhibited synergism at 166 several concentrations for all four cervical cancer cell lines (Table S3) and invasion of the spheroids was similar to the cytotoxicity curves obtained for the 2D cultures 178 ( Fig. 2a -c) . Similar data were obtained when the drug combination was tested on 3D spheroids 179 generated from SiHa cells. S63845 at 2 µM was able to sensitize the spheroids to A1331852, 180 reflected in dose-dependent inhibition of spheroid growth and invasion. Similarly, A1331852 181 at 2 µM was able to sensitize the spheroids to S63845 (Fig. S1 ). Taken together, the effect of 182 combination of A1331852/S63845 observed in the spheroid model was consistent with the 183 monolayer culture data, suggesting that this drug combination may be effective in vivo. 184 S63845 only modestly sensitised HeLa cells to ABT-199 in monolayer culture (Fig.  185 2a). The combination (ABT-199/S63845) however, had minimal effect on the growth and 186 invasion of the 3D HeLa spheroids even at the highest combination concentration used, 187
indicating higher combination concentrations may be required to inhibit growth and invasion 188 of the spheroids (Fig. S2 ).
Cervical cancer cell lines were sensitive to co-inhibition of BCL-2 and MCL-1 190
In HeLa cells, 0.25 µM S63845 shifted the dose-response curve to the left (Fig. 4a ) sensitizing 191 the cells to ABT-199 by 6-fold (Table S4 ). An increase in concentration of S63845 to 0.5 µM, 192 resulted in a significant shift of the dose-response curve to the left (Fig. 4a ) and the cells were 193 sensitized to ABT-199 by 13-fold (Table S4) . 194
The drug interaction analyses demonstrated that combination of ABT-199 with 0.25 195 µM of S63845 could not be determined. At the concentrations tested, the poor efficacy of the 196 combination treatment, meant that we were unable to conduct drug interaction analyses (Table  197 S5). Concentrations of ABT-199 > 1 µM combined with 0.25 µM S63845 were antagonistic 198 (Table S5 ). The combination of S63845 only resulted in synergism at 0.5 µM S63845 199 combined with concentrations of ABT-199 > 1 µM (Table S5) Table  204 S4). The sensitization increased to > 40-fold at a concentration of 1 µM S63845 and 2 µM of 205 S63845 ( Fig. 4b & Table S4 ) and drug interaction analyses demonstrated strong synergism at 206 multiple doses of S63845 and ABT-199 (Table S5) . 207
In SiHa cells, S63845 at 0.5 µM ( Fig. 4c & Table S4 ) and 1 µM (Fig. 4c ) only sensitized 208
SiHa cells to ABT-199 by 2-fold (Table S4 ). This sensitization only increased to 3-fold (Table  209 S4) when the concentration of S63845 was increased to 2 µM (Fig. 4c) . 210 Combination with 0.5 µM of S63845 modestly sensitised the CaSki cells to ABT-199 211 by 6-fold ( Fig. 4d & Table S4 ). The fold-sensitisation increased (14 -fold), when concentration 212 of S63845 was increased to 1 µM and 2 µM ( Fig. 4d & Table S4 ). Drug interaction analyses 213 indicated that the drug combinations demonstrated strong synergism at several concentrations 214 of S63845 and ABT-199 (Table S5 ). Collectively, the findings demonstrate that inhibition of 215 either BCL-2 or BCL-XL alone is not adequate to kill the CaSki cells. Co-inhibition of MCL-216 1 with either BCL-XL or BCL-2 appears to be essential to kill the cells. 217
These data demonstrate that there was a greater response to co-inhibition of MCL-1 218 and BCL-XL. Cells responded to combination of S63845 and A1331852 more rapidly at low 219 concentrations. In contrast, the response to co-inhibition of MCL-1 and BCL-2 was variable 220
suggesting that other cell death mechanisms that do not rely on these proteins may be involved. 221 The sensitization obtained in the monolayer culture was analogous to the data obtained 252 with the 3D spheroid studies. The 3D HeLa spheroids were sensitized to A1331852 by S63845 253 but sensitization was only obvious following treatment with 1 µM of S63845, indicating that 254 higher concentrations of S63845 are required to sensitize spheroids to A1331852 compared to 255 concentration of S63845 required to see the same sensitization effect in monolayer culture. 256
One explanation for the need of higher drug combination concentrations in the spheroids, could 257 be attributed to the 3D orientation of the tumor cells which is likely to limit diffusion of drugs 258 to the cells in the center of the spheroid. 259 C33A cells were sensitive to combinations of ABT-199 and S63845. Given that the 260 C33A cells also responded effectively to a combination of A1331852 and S63845, it appears 261 that co-inhibition of either BCL-2 or BCL-XL with MCL-1 is sufficient to trigger cell death in 262 C33A cells. SiHa cells responded poorly to combination of ABT-199 and S63845 but the cells 263 were sensitive to combination of A1331852 and S63845. Therefore, SiHa cells may be 264 dependent on BCL-XL and MCL-1 for survival rather than BCL-2. Therefore, it is possible 265 that that co-inhibition of BCL-2 and MCL-1 may have led to overexpression of BCL-XL as a 266 compensatory survival adaptation which has been reported in other cancer cell lines. 
